NANOGENIX Trademark

Trademark Overview


On Friday, March 24, 2023, a trademark application was filed for NANOGENIX with the United States Patent and Trademark Office. The USPTO has given the NANOGENIX trademark a serial number of 97856817. The federal status of this trademark filing is NON-FINAL ACTION - MAILED as of Friday, January 12, 2024. The NANOGENIX trademark is filed in the Pharmaceutical Products category with the following description:

Anti-infectives; Antibiotic preparations; Antibiotics; Antibiotics for human use; Antibiotics for use in dentistry; Diagnostic biomarker reagents for medical purposes; Diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, cancer; Diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, immune disorders; Diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, genetic disorders; Diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, diabetes; Diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, skin cutaneous disorders; Diagnostic kits comprised of medical diagnostic reagents and assays for test...
nanogenix

General Information


Serial Number97856817
Word MarkNANOGENIX
Filing DateFriday, March 24, 2023
Status641 - NON-FINAL ACTION - MAILED
Status DateFriday, January 12, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesAnti-infectives; Antibiotic preparations; Antibiotics; Antibiotics for human use; Antibiotics for use in dentistry; Diagnostic biomarker reagents for medical purposes; Diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, cancer; Diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, immune disorders; Diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, genetic disorders; Diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, diabetes; Diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, skin cutaneous disorders; Diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, liver diease; Diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, renal disease; Diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, pain; Diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, cardiovascular disorders; Diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, neurological disorders; Diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, blood disorders; Diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, viruses; Diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, bacteria infections; Diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, antibodies; Diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, DNA; Diagnostic media for bacteriological cultures; Diagnostic preparations for medical purposes; Diagnostic preparations for veterinary purposes; Diagnostic radiopharmaceutical agent for use in PET imaging; Diagnostic radiopharmaceutical preparations; Diagnostic reagents for medical use; Diagnostic test patch for application to the skin for determining allergic reactions; Drug delivery agents in the form of NANO PARTICLES that facilitate the delivery of pharmaceutical preparations; Drug delivery agents in the form of NANO TECHNOLOGY that facilitate the delivery of pharmaceutical preparations; Drug delivery agents in the form of medical devices that facilitate the delivery of pharmaceutical preparations; Drug delivery agents in the form of micro particles that facilitate the delivery of pharmaceutical preparations; Drug delivery agents in the form of creams that facilitate the delivery of pharmaceutical preparations; Drug delivery agents in the form of gels that facilitate the delivery of pharmaceutical preparations; Drug delivery agents in the form of patches that facilitate the delivery of pharmaceutical preparations; Food for infants; Food supplements; Gene therapy products, namely, genetically engineered tissues for transplant purposes; Genetic identity tests comprised of reagents for medical purposes; Pharmaceutical agents for epidermis; Pharmaceutical agents for treating physically caused lesions; Pharmaceutical preparation for skin care; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for skin care; Pharmaceutical preparations for skin wounds; Pharmaceutical preparations for suppressing tumors; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; Pharmaceutical preparations for the prevention of CANCER; Pharmaceutical preparations for the relief of insect bites; Pharmaceutical preparations for the treatment and prevention of CANCER; Pharmaceutical preparations for the treatment and prevention of BACTERIA INFECTIONS; Pharmaceutical preparations for the treatment and prevention of PRECANCEROUS CONDITIONS; Pharmaceutical preparations for the treatment and prevention of VIRAL INFECTIONS; Pharmaceutical preparations for the treatment and prevention of Immune disorders; Pharmaceutical preparations for the treatment and prevention of genetic disorders; Pharmaceutical preparations for the treatment and prevention of gene disorders; Pharmaceutical preparations for the treatment and prevention of cardiovascular disease; Pharmaceutical preparations for the treatment and prevention of neurological disorders; Pharmaceutical preparations for the treatment and prevention of Pain; Pharmaceutical preparations for the treatment and prevention of cutaneous diseases; Pharmaceutical preparations for the treatment and prevention of dental diseases; Pharmaceutical preparations for the treatment and prevention of respiratory disorders; Pharmaceutical preparations for the treatment and prevention of diabetes; Pharmaceutical preparations for the treatment and prevention of alzheimers disease; Pharmaceutical preparations for the treatment and prevention of renal disorders; Pharmaceutical preparations for the treatment and prevention of obesity; Pharmaceutical preparations for the treatment and prevention of mental health conditions; Pharmaceutical preparations for the treatment and prevention of blood disorders; Pharmaceutical preparations for the treatment and prevention of parkinson's disease; Pharmaceutical preparations for the treatment and prevention of liver disease; Pharmaceutical preparations for the treatment of autoimmune diseases; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for the treatment of musculo-skeletal disorders; Pharmaceutical preparations for the treatment of viral diseases; Pharmaceutical preparations for the treatment of viral infections; Pharmaceutical preparations for the treatment of PRECANCEROUS CONDITIONS; Pharmaceutical preparations for the treatment of CANCER; Pharmaceutical preparations for treating allergic rhinitis and asthma; Pharmaceutical preparations for treating epidermal problems; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for wounds; Pharmaceutical preparations for INFECTIOUS DISEASE; Pharmaceutical preparations for GENE THERAPY; Pharmaceutical preparations for IMMUNOTHERAPY; Pharmaceutical preparations for Nanoparticle Technology; Pharmaceutical preparations for Nano Particles; Pharmaceutical preparations for Nano technology; Pharmaceutical preparations for vaccines; Pharmaceutical preparations for vaccination; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical products for the treatment of cancer; Pharmaceutical products for the treatment of infectious diseases; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Pharmaceutical products for the treatment of viral diseases; Pharmaceutical products for treating respiratory diseases and asthma; Topical gel for medical and therapeutic treatment of SKIN CANCER; Topical gel for medical and therapeutic treatment of PRECANCEROUS CONDITIONS; Topical gel for medical and therapeutic treatment of CANCER; Topical gel for medical and therapeutic treatment of dermatologic disease; Anti-cancer preparations; Antibacterial pharmaceuticals; Antimicrobial preparations for inhibiting microbiological decomposition in food, beverages, animal feed and pharmaceuticals; Biological preparations for the treatment of cancer; Biological preparations for the treatment of CANCER; Biological preparations for the treatment of genetic disorders; Biological preparations for the treatment of viruses; Biological preparations for the treatment of bacteria infections; Biological preparations for the treatment of skin cutaneous disorders; Biological preparations for the treatment of diabetes; Biological preparations for the treatment of cardiovascular disorders; Biological preparations for the treatment of neurological disorders; Cardiovascular pharmaceutical preparations; Cardiovascular pharmaceuticals; Chemical preparations for pharmaceutical or medical purposes, namely, for CANCER; Chemical preparations for pharmaceutical or medical purposes, namely, for PRECANCEROUS CONDITIONS; Chemical preparations for pharmaceutical or medical purposes, namely, for Nanoparticle technology; Dermatological pharmaceutical products; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; Intravenous fluids used for rehydration, nutrition and the delivery of pharmaceutical preparations; Medical diagnostic reagents; Medical diagnostic test strips for use in the field of cancer; Medical diagnostic test strips for use in the field of dermatology; Medical diagnostic test strips for use in the field of viral diseases; Medical diagnostic test strips for use in the field of bacteria diseases; Medical diagnostic test strips for use in the field of saliva testing; Medical diagnostic test strips for use in the field of urine testing; Medical diagnostic test strips for use in the field of blood testing; Medicated beauty soap; Medicated shampoo bars; Medicated shampoos; Medicated skin care preparations; Medicated hair serums; Medicinal preparations for the treatment of infectious diseases and for use in oncology; Mixed antibiotic preparations; Nutritional supplement meal replacement bars for boosting energy; Ocular pharmaceuticals; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, for the treatment of bacteria-based diseases, and for the treatment of diabetes, and anti - infective preparations, antiviral preparations, antibiotics, antifungal preparations and vaccines; Pharmaceutical products for the treatment of joint disease; Pharmaceuticals, namely, anti-infectives; Plant extracts for pharmaceutical purposes; Preparations for detecting genetic predispositions for medical purposes; Preparations for detecting mutation in prion genes for medical purposes; Radioactive pharmaceutical preparations for use in vivo diagnostic or therapeutic use; Radiopharmaceutical imaging and detection agents for diagnosing and monitoring cancer; Reagents for use in medical genetic testing; Veterinary diagnostic reagents

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, April 17, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameNOT AVAILABLE
Party Type10 - Original Applicant
Legal Entity Type01 - Individual
AddressGrayslake, IL 60030

Trademark Events


Event DateEvent Description
Friday, January 12, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, January 12, 2024NON-FINAL ACTION E-MAILED
Friday, January 12, 2024NON-FINAL ACTION WRITTEN
Tuesday, December 19, 2023ASSIGNED TO EXAMINER
Monday, April 17, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, March 28, 2023NEW APPLICATION ENTERED